Zatolmilast

Zatolmilast is a investigational new drug that is being evaluated to treat fragile X syndrome.^[1] It is a PDE4D allosteric inhibitor.^[2]

Zatolmilast

Clinical data
Other names	BPN-14770
Legal status
Legal status	Investigational
Identifiers
IUPAC name 2-[4-[[2-(3-chlorophenyl)-6-(trifluoromethyl)pyridin-4-yl]methyl]phenyl]acetic acid
CAS Number	1606974-33-7
PubChem CID	90111638
IUPHAR/BPS	10451
DrugBank	DB14790
ChemSpider	75533972
UNII	G786V328X6
KEGG	D12173
ChEMBL	ChEMBL4541964
PDB ligand	KR7 (PDBe, RCSB PDB)
Chemical and physical data
Formula	C21H15ClF3NO2
Molar mass	405.80 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=CC(=CC(=C1)Cl)C2=NC(=CC(=C2)CC3=CC=C(C=C3)CC(=O)O)C(F)(F)F
InChI InChI=1S/C21H15ClF3NO2/c22-17-3-1-2-16(12-17)18-9-15(10-19(26-18)21(23,24)25)8-13-4-6-14(7-5-13)11-20(27)28/h1-7,9-10,12H,8,11H2,(H,27,28) Key:LTSUMTMGJHPGFX-UHFFFAOYSA-N